SCHEMBL6107131

SCHEMBL6107131

CN(c1ccc(F)cc1C(=O)Nc1ccc(Cl)cn1)C1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NR3C1 P04150 3/20 0.46
▸ F10 P00742 2/20 0.46
▸ MAPT P10636 5/20 0.43
▸ MEN1 O00255 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ POLB P06746 1/20 0.43
▸ TP53 P04637 2/20 0.42
▸ THRB P10828 1/20 0.42
▸ USP30 Q70CQ3 1/20 0.42
▸ NPSR1 Q6W5P4 2/20 0.42
▸ CNR1 P21554 1/20 0.42
▸ GPR35 Q9HC97 1/20 0.42
▸ GPR55 Q9Y2T6 1/20 0.42
▸ IDO1 P14902 1/20 0.41
▸ TDO2 P48775 1/20 0.41
▸ USP2 O75604 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6109873 0.93 NR3C1 (0.49) NR3C1F10MAPTMEN1KMT2A
SCHEMBL6108331 0.90 NR3C1 (0.46) NR3C1F10MAPTMEN1KMT2A
SCHEMBL6106463 0.84 F10 (0.57) NR3C1F10USP30IDO1TDO2
SCHEMBL5758729 0.83 MEN1 (0.48) NR3C1MAPTMEN1KMT2APOLB
SCHEMBL6109232 0.83 F10 (0.62) NR3C1F10
SCHEMBL6107823 0.82 F10 (0.55) NR3C1F10MAPTTP53THRB
SCHEMBL6106717 0.82 F10 (0.47) F10USP30IDO1TDO2SMN1; SMN2
SCHEMBL6106784 0.82 F10 (0.52) F10MEN1KMT2AUSP30SMN1; SMN2
SCHEMBL6107135 0.81 F10 (0.47) NR3C1F10MAPTTP53
SCHEMBL6107173 0.81 F10 (0.50) F10USP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7129245-B2 Anticoagulants which act selectively on factor Xa; fast acting; oral; do not interfere with lysis of blood clots ELI LILLY AND COMPANY (US) 2006-10-31 — — US disclosed
US-20050282862-A1 Aromatic amides BEIGHT DOUGLAS W 2005-12-22 — — US disclosed
EP-1140903-B1 AROMATIC AMIDES LILLY CO ELI (US) 2004-08-04 — — EP disclosed
US-6759414-B2 ANTICOAGULANTS WHICH ACT SELECTIVELY ON FACTOR XA; FAST ACTING; ORAL; DO NOT INTERFERE WITH LYSIS OF BLOOD CLOTS ELI LILLY AND COMPANY 2004-07-06 — — US disclosed
US-20040029874-A1 Aromatic amides BEIGHT DOUGLAS WADE (US) 2004-02-12 — — US disclosed
US-6635657-B1 Pyridine derivatives; anticoagulants ELI LILLY AND COMPANY 2003-10-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040029874-A1 Aromatic amides F11, F12, F5 NR3C1 4435/4885F10 12/4885MAPT 2723/4885
US-20050282862-A1 Aromatic amides F11, F12, F5 NR3C1 4435/4885F10 12/4885MAPT 2723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback